12 recruiting. 12 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 12 |
| Phase 1 | 3 | Recruiting 3 |
| Phase 3 | 2 | Recruiting 2 |
Follow Bendamustine: new trials by email Literature Review of Bendamustine trials Research Report on Bendamustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) MK-1045, Rituximab, Rituximab biosimilar - Follicular Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-06-22 | 2026-10-26 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis TRX319, Bendamustine - Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS) | Phase 1 / Phase 2 | Recruiting | Tr1X, Inc. | 39 | 2026-03-01 | 2026-09-21 |
| A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma Rocbrutinib, Bendamustine, Rituximab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 150 | 2025-11-27 | 2025-12-16 |
| BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma Bendamustine, Rituximab, Cytarabine - Mantle Cell Lymphoma, Lymphoma | Phase 2 | Recruiting | Christine Ryan | 60 | 2025-04-22 | 2026-02-20 |
| Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM Zanubrutinib, Bendamustine, Rituximab - Waldenstrom Macroglobulinemia | Phase 2 | Recruiting | Massachusetts General Hospital | 65 | 2024-12-20 | 2026-09-01 |
| A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma Zanubrutinib, Polatuzumab Vedotin, Bendamustine - Refractory or Relapsed Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 36 | 2024-08-31 | 2024-08-15 |
| Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy Epcoritamab, Lenalidomide, Rituximab - Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | Recruiting | University of Birmingham | 284 | 2023-09-04 | 2026-05-05 |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) Zilovertamab vedotin, Rituximab, Gemcitabine - DLBCL, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 290 | 2022-01-14 | 2026-11-03 |
| DALY II USA/ MB-CART2019.1 for DLBCL zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine - Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Miltenyi Biomedicine GmbH | 315 | 2021-05-25 | 2026-07-13 |
| Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Bendamustine, Cyclophosphamide - Hematopoietic and Lymphoid System Neoplasm | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 25 | 2020-03-13 | 2026-07-16 |
| CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma ATLCAR.CD30 T cells, Bendamustine, Fludarabine - Peripheral T Cell Lymphoma | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 20 | 2019-09-17 | 2026-09-24 |
Lymphoma (4) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Central Nervous System Neoplasms (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1) · Waldenstrom Macroglobulinemia (1)
Merck Sharp & Dohme LLC (2) · Christine Ryan (1) · Fred Hutchinson Cancer Center (1) · Guangzhou Lupeng Pharmaceutical Company LTD. (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Miltenyi Biomedicine GmbH (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Tr1X, Inc. (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Birmingham (1)
United States (9) · China (4) · Argentina (2) · Australia (2) · Canada (2) · Chile (2) · Greece (2) · Israel (2) · Italy (2) · Poland (2) · South Korea (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Brazil (1) · Colombia (1)
Andrew Branagan, MD, PhD (1) · Anne Beaven, MD (1) · Christine Ryan, MD (1) · Issa F Khouri (1) · Johanna Theruvath, MD (1) · Lorenzo Iovino, MD, PhD (1)
2025 (1)